XBIO
vs
S&P 500
XBIO
S&P 500
Over the past 12 months, XBIO has underperformed S&P 500, delivering a return of -47% compared to the S&P 500's +14% growth.
Stocks Performance
XBIO vs S&P 500
Performance Gap
XBIO vs S&P 500
Performance By Year
XBIO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Xenetic Biosciences Inc
Glance View
Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The firm's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. The company uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.